Salix calls it quits on an inversion over mounting political pressure

Damian Garde Specialty drugmaker Salix Pharmaceuticals is backing out of a $ 2.7 billion deal that would have given it an Irish domicile–and thus a lower tax rate–in the ...

Pfizer, Ranbaxy prevail in antitrust fight over Lipitor generics

Tracy Staton Pfizer and Ranbaxy Laboratories persuaded a U.S. judge to toss out an antitrust lawsuit accusing them of conspiring to delay generic versions of the cholesterol-fighting ...

Move by French government encourages docs to use Roche’s Avastin over Lucentis

Eric Palmer Roche's Avastin is often prescribed off label as a cheaper alternative to its Lucentis for treating wet age-related macular degeneration. Now French lawmakers are encouraging ...

International brouhaha over AbbVie misstep highlights U.K.’s M&A rules

John Carroll Analysts generally believe that big takeovers are easier to pull off under the U.K.'s M&A guidelines. But you'd better not ignore the very specific rules of ...

FDA forces Lunesta dosage drop over dozing fears

Carly Helfand The FDA is making another move to ensure the safety of sleep drugs, and this time the target is Lunesta, requiring maker Sunovion to change the drug's label and lower ...

Nasdaq volatility delays IPO, Almirall pulls drug over price, Topotarget to merge as PDUFA nears

Nick Paul Taylor Welcome to this week's edition of our EuroBiotech Report, in which we have news of how the rise and fall of U.S. biotech and med tech stocks is shaping decisions ...

Amarin lashes out at FDA with lawsuit over Vascepa exclusivity

Eric Palmer Amarin, which has faced a series of setbacks getting its fish oil pill to market, is lashing out at the FDA for some of its problems, Bloomberg reports. FiercePharma News

Boehringer says it’s fighting 2,000 lawsuits over Pradaxa safety

Tracy Staton Pradaxa has become a bigger legal headache for Boehringer Ingelheim. The German drugmaker says it's facing more than 2,000 lawsuits in the U.S., filed by patients claiming ...

As biosims win nods in Europe and India, debate over naming rights heats up

Alok Saboo What's in a name? In the pharmaceutical world, the answer to this question is no simple matter. Drugmakers, biotechs and their generic rivals are squabbling over the ...

Drug buyers sue Novo Nordisk over ‘wrongful’ delays to diabetes generic

Carly Helfand The Federal Trade Commission may now have the right to challenge pay-for-delay deals, but drugmakers can still stall the launches of competing generic products. And that's ...

Compounder Strikes Preliminary $100M Deal Over Meningitis Outbreak

esilverman More than a year after an outbreak of fungal meningitis was traced to the New England Compounding Center and caused the worst public health crisis in the US in decades, ...

AstraZeneca’s Nexium gets a Korean competitor to chase it over the patent cliff

Carly Helfand The difference between magnesium salt and strontium salt may be enough to threaten U.S. sales of AstraZeneca's blockbuster Nexium–starting now. Reports say South ...
Page 2 of 812345...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS